PIPELINE
  • Indication
    • Uveitis (macular edema associated with uveitis)

      Diabetic Macular Edema

    • Progressive Myopia

    • Presbyopia

  • Commercial Rights
    • Greater China & South Korea

    • Greater China & South Korea

    • Greater China & South Korea

  • Partners
    • Preclinical
    • Phase I
    • Phase II
    • Phase III
    • NDA
    • Marketed
    • US
      US
    • US
    • US
    Arctic Vision China R&D Progress Partners R&D Progress
ABOUT US

Arctic Vision is a clinical stage specialty ophthalmology company focused on developing breakthrough therapies with high commercial value to address the unmet clinical needs. Our vision is to become a leading ophthalmology company in China and lead China's ophthalmology market. Arctic Vision is established by top-tier life sciences investors, and led by an elite team of ophthalmic industry veterans with substantial and compelling China and global experiences in R&D and commercialization of eye care products. 

  • Eddy WuPh.D.
    Founder and CEO
  • Qing Liu M.D., Ph.D.
    Vice President, Clinical and Regulatory Affairs
  • York Chen M.D., EMBA
    Vice President, Operations and Commercial Planning
  • David MalekMBA
    Chief Business Officer
  • Chris FangMBA
    Senior Director, Corporate Development
  • Ping ChengCA/CFA
    Associate Vice President, Finance
ADDRESS
Room 1732, Century Century Tower 1, Century Avenue, Pudong New District, Shanghai, China
SUBSCRIBE TO OUR NEWSLETTER
Subscribe
Copyright © 2020 Arctic Vision (Shanghai) Biotechnology Co., Ltd.